Engineered immune cells take on deadly brain cancer

NCT ID NCT05353530

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new therapy made from a patient's own immune cells, modified to better target and attack glioblastoma and other high-grade gliomas. The cells are designed to recognize a protein called CD70 found on these tumors. The main goals are to see if the treatment is safe and possible to deliver in a small group of adults and children.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 8R-70CAR T cells (a type of immune cell modified to target CD70 on tumor cells)
What this could lead to: If successful, this could point toward a new treatment option for glioblastoma and other aggressive brain tumors that are hard to treat.
What could go wrong: This is an early phase 1 trial with only 39 participants, so it is primarily testing safety, not effectiveness. The treatment may cause serious side effects or fail to control the tumor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

University of Florida Health
RECRUITING

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.